Literature DB >> 23024287

A physiologically based in silico kinetic model predicting plasma cholesterol concentrations in humans.

Niek C A van de Pas1, Ruud A Woutersen, Ben van Ommen, Ivonne M C M Rietjens, Albert A de Graaf.   

Abstract

Increased plasma cholesterol concentration is associated with increased risk of cardiovascular disease. This study describes the development, validation, and analysis of a physiologically based kinetic (PBK) model for the prediction of plasma cholesterol concentrations in humans. This model was directly adapted from a PBK model for mice by incorporation of the reaction catalyzed by cholesterol ester transfer protein and contained 21 biochemical reactions and eight different cholesterol pools. The model was calibrated using published data for humans and validated by comparing model predictions on plasma cholesterol levels of subjects with 10 different genetic mutations (including familial hypercholesterolemia and Smith-Lemli-Opitz syndrome) with experimental data. Average model predictions on total cholesterol were accurate within 36% of the experimental data, which was within the experimental margin. Sensitivity analysis of the model indicated that the HDL cholesterol (HDL-C) concentration was mainly dependent on hepatic transport of cholesterol to HDL, cholesterol ester transfer from HDL to non-HDL, and hepatic uptake of cholesterol from non-HDL-C. Thus, the presented PBK model is a valid tool to predict the effect of genetic mutations on cholesterol concentrations, opening the way for future studies on the effect of different drugs on cholesterol levels in various subpopulations in silico.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23024287      PMCID: PMC3494263          DOI: 10.1194/jlr.M031930

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  67 in total

1.  Smith-Lemli-Opitz syndrome: deficient delta 7-reductase activity in cultured skin fibroblasts and chorionic villus fibroblasts and its application to pre- and postnatal detection.

Authors:  R J Wanders; G J Romeijn; F Wijburg; R C Hennekam; J de Jong; R A Wevers; G Dacremont
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

2.  Free cholesterol-induced cytotoxicity a possible contributing factor to macrophage foam cell necrosis in advanced atherosclerotic lesions.

Authors:  I Tabas
Journal:  Trends Cardiovasc Med       Date:  1997-10       Impact factor: 6.677

3.  Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences.

Authors:  D J Quick; M L Shuler
Journal:  Biotechnol Prog       Date:  1999 May-Jun

Review 4.  Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans.

Authors:  J M Dietschy; S D Turley; D K Spady
Journal:  J Lipid Res       Date:  1993-10       Impact factor: 5.922

Review 5.  Comparative effects of lipid-lowering therapies.

Authors:  Michael H Davidson; Peter P Toth
Journal:  Prog Cardiovasc Dis       Date:  2004 Sep-Oct       Impact factor: 8.194

6.  A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity.

Authors:  A M Hissink; B Van Ommen; J Krüse; P J Van Bladeren
Journal:  Toxicol Appl Pharmacol       Date:  1997-08       Impact factor: 4.219

7.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

8.  Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Authors:  Laura K Potter; Dennis L Sprecher; Max C Walker; Frank L Tobin
Journal:  J Lipid Res       Date:  2009-03-11       Impact factor: 5.922

9.  Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in men with different apoE phenotypes.

Authors:  H Gylling; T A Miettinen
Journal:  J Lipid Res       Date:  1992-09       Impact factor: 5.922

10.  Dynamical modeling of the cholesterol regulatory pathway with Boolean networks.

Authors:  Gwenael Kervizic; Laurent Corcos
Journal:  BMC Syst Biol       Date:  2008-11-24
View more
  12 in total

1.  Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations.

Authors:  Niek C A van de Pas; Johan A C Rullmann; Ruud A Woutersen; Ben van Ommen; Ivonne M C M Rietjens; Albert A de Graaf
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-09       Impact factor: 2.745

2.  A mathematical model of in vitro hepatocellular cholesterol and lipoprotein metabolism for hyperlipidemia therapy.

Authors:  Yuri Efremov; Anastasia Ermolaeva; Georgiy Vladimirov; Susanna Gordleeva; Andrey Svistunov; Alexey Zaikin; Peter Timashev
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

3.  BOOGIE: Predicting Blood Groups from High Throughput Sequencing Data.

Authors:  Manuel Giollo; Giovanni Minervini; Marta Scalzotto; Emanuela Leonardi; Carlo Ferrari; Silvio C E Tosatto
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.

Authors:  Jeffrey E Ming; Ruth E Abrams; Derek W Bartlett; Mengdi Tao; Tu Nguyen; Howard Surks; Katherine Kudrycki; Ananth Kadambi; Christina M Friedrich; Nassim Djebli; Britta Goebel; Alex Koszycki; Meera Varshnaya; Joseph Elassal; Poulabi Banerjee; William J Sasiela; Michael J Reed; Jeffrey S Barrett; Karim Azer
Journal:  Gene Regul Syst Bio       Date:  2017-06-22

5.  The Virtual Anemia Trial: An Assessment of Model-Based In Silico Clinical Trials of Anemia Treatment Algorithms in Patients With Hemodialysis.

Authors:  Doris H Fuertinger; Alice Topping; Franz Kappel; Stephan Thijssen; Peter Kotanko
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-01-31

6.  An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway.

Authors:  James Lu; Katrin Hübner; M Nazeem Nanjee; Eliot A Brinton; Norman A Mazer
Journal:  PLoS Comput Biol       Date:  2014-03-13       Impact factor: 4.475

Review 7.  Computationally Modeling Lipid Metabolism and Aging: A Mini-review.

Authors:  Mark T Mc Auley; Kathleen M Mooney
Journal:  Comput Struct Biotechnol J       Date:  2014-11-15       Impact factor: 7.271

8.  Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models.

Authors:  R J Allen; T R Rieger; C J Musante
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-17

9.  Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.

Authors:  Kapil Gadkar; James Lu; Srikumar Sahasranaman; John Davis; Norman A Mazer; Saroja Ramanujan
Journal:  J Lipid Res       Date:  2015-11-01       Impact factor: 5.922

Review 10.  Linear-In-Flux-Expressions Methodology: Toward a Robust Mathematical Framework for Quantitative Systems Pharmacology Simulators.

Authors:  Sean T McQuade; Ruth E Abrams; Jeffrey S Barrett; Benedetto Piccoli; Karim Azer
Journal:  Gene Regul Syst Bio       Date:  2017-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.